TOKYO, Oct 3, 2017 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Seren Pharmaceuticals Inc. announced today that Sato Pharma and Eisai will co-promote a new triazole class oral antifungal agent (development code: BFE1224, "the agent") containing the active ingredient fosravuconazole L-lysine ethanolate ("fosravuconazole") in Japan, based on an agreement between the three companies. The agent is currently under regulatory review for the treatment of onychomycosis.
After receiving regulatory approval, Sato Pharma will begin distributing the agent, and Sato Pharma and Eisai will jointly provide information on its proper use.
Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma (formerly known as "Brain Factory Co., Ltd."), granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan. In 2014, Seren Pharma concluded an agreement with Sato Pharma, granting them the development and commercialization rights, and both companies continued to develop the agent for treating onychomycosis. In January 2017, Sato Pharma applied for marketing authorization for the agent.
Sato Pharma, Eisai, and Serena Pharma will cooperate to maximize the value of fosravuconazole in order to fulfil the unmet medical needs of patients with fungal diseases.
About fosravuconazole
Fosravuconazole is a new oral antifungal component developed by Eisai. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells.
About onychomycosis
Onychomycosis is a fungal infection of the toenails or fingernails. Pathogens enter the skin through the small separations between the nail and the nail bed, and eventually infect the nail itself. It is a common nail disease, with an estimated approximately 11 million sufferers in Japan. While not life-threatening, it is an important public health issue, as if left untreated, it causes local tenderness due to deformation and thickening of the nails, limits physical activity due to pain, can spread to family members, and can lead to an outbreak of secondary fungal and bacterial infections. Early treatment of onychomycosis is necessary to prevent loss of QOL (Quality of Life).
About Sato Pharmaceutical Co., Ltd.
Sato Pharmaceutical Co., Ltd., operating under it's corporate philosophy of "Healthcare Innovation", is a pharmaceutical company that provides effective, safe, and highquality products for practicing selfcare, while always keeping the health of its customers in mind. In addition to its main consumer healthcare business, Sato Pharmaceutical also develops and provides highly original products primarily in the field of dermatology.
For more information about Sato Pharmaceutical Co., Ltd., please visit, www.sato-seiyaku.co.jp/company/en/index.html.
About Seren Pharmaceuticals Inc.
Seren Pharmaceuticals is a specialized R&D-based pharmaceutical company which in-licenses pharmaceutical candidates for which POC (Proof of Concept) has already been established but development has stalled due to low-development priority, despite high medical needs and commercial potential. Seren Pharmaceuticals makes use of in-house specialist groups and networking to conduct drug discovery and in-licensing from a fresh perspective, and through efficient development, expediates commercialization.
For more information about Seren Pharmaceuticals Inc., please visit www.serenpharma.com.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
